Comparative Pharmacology
Head-to-head clinical analysis: DELSYM versus TUZISTRA XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELSYM versus TUZISTRA XR.
DELSYM vs TUZISTRA XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dextromethorphan is a non-competitive NMDA receptor antagonist and sigma-1 receptor agonist, which suppresses cough by elevating the threshold for coughing in the medullary cough center.
Tuzistra XR is a combination of codeine (an opioid agonist) and promethazine (a phenothiazine derivative with antihistaminic, sedative, and anticholinergic effects). Codeine binds to mu-opioid receptors in the CNS, inhibiting cough reflex. Promethazine acts as a histamine H1 receptor antagonist and may have additional central anticholinergic and sedative effects.
60 mg orally every 12 hours (extended-release suspension).
Initial: 25 mg orally twice daily; may increase to 50 mg twice daily after 1 week based on tolerability; maximum 50 mg twice daily.
None Documented
None Documented
Terminal elimination half-life of dextromethorphan is approximately 11 hours (range 9-14 hours) in extensive metabolizers; in poor metabolizers (CYP2D6 deficiency), half-life can exceed 24 hours, leading to accumulation.
Terminal elimination half-life is 7 hours for the parent drug; clinically, this supports twice-daily dosing for sustained symptom relief.
Renal excretion of unchanged drug and metabolites, primarily dextrorphan glucuronide; <5% excreted unchanged in urine. Biliary/fecal elimination is negligible.
Primarily hepatic metabolism via glucuronidation; approximately 20% of the dose is excreted unchanged in urine, and 80% is eliminated as metabolites in feces via biliary excretion.
Category C
Category C
Antitussive
Antitussive/decongestant combination